Resources

Open Trials- February 2020

Breast Cancer Trials:

A study of xentuzumab + everolimus and exemestane VS everolimus and exemestane in post-menopausal women with HR+ / HER2 – metastatic breast cancer and non-visceral disease (Xenera 1)

https://clinicaltrials.gov/ct2/show/NCT03659136?term=1280-0022&draw=2&rank=1

A study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate, VS Treatment of Investigator’s Choice for HER2 +, Unresectable and/or Metastatic Breast Cancer in Subjects Pretreated with Prior Standard of Care therapies including T-DM1 (DESTINY-Breast 02)

https://clinicaltrials.gov/ct2/show/NCT03523585?term=DS8201-A-U301&rank=1

A Study of DS8201a, an Anti-HER2-Antibody Drug Conjugate (ADC), versus Treatment of Investigator’s Choice for HER2-low Unresectable and/or Metastatic Breast Cancer.

(DESTINY-Breast 04)

https://clinicaltrials.gov/ct2/show/NCT03326674

A Prospective Registry study to Evaluate the Effect of the DCISionRT test on Treatment Decisions in Patient with DCIS Following Breast Conserving Therapy

(Available Late December 2020)

https://clinicaltrials.gov/ct2/show/NCT03448926?term=preludedx&draw=2&rank=1

For questions regarding this study, please contact 480-398-7671


Lung Cancer Trials:

Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion (DUBLIN-3)

https://clinicaltrials.gov/ct2/show/NCT02504489

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

https://clinicaltrials.gov/ct2/show/NCT02973789

A Study of Pembrolizumab (Keytruda) + Lenvatinib or placebo for treatment Naïve Metastatic Non-Small Cell Lung Cancer (NSCLC) with TPS ≥ 1% (LEAP 007)

https://clinicaltrials.gov/ct2/show/NCT03829332?term=mk7902-007&draw=2&rank=1

For questions regarding this study, please contact 480-398-7671


Melanoma Trials:

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients (MAVIS)

Enrollment on this trial is on hold. Please contact Ironwood Cancer & Research Centers for status update

For questions, please contact 480-398-7671


Prostate Trials:

A Study of Talazoparib + Enzalutamide vs Enzalutamide in Metastatic Castration-Resistant

Prostate Cancer

(Talapro-2)

  https://clinicaltrials.gov/ct2/show/NCT03395197?term=talapro+2&draw=2&rank=1


Lymphoma Studies:

Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin’s Lymphoma (UNITY-NHL)

https://clinicaltrials.gov/ct2/show/NCT02793583?term=unity+205&draw=2&rank=1

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL) (CHRONOS-4)

https://clinicaltrials.gov/ct2/show/NCT02626455?term=chronos+4&draw=2&rank=1

For questions regarding this study, please contact 480-398-7671


Solid Tumor Trials:

A Study of Selective Pan-FGFR inhibitor Debio 1347 in Subjects with Solid Tumors Harboring a

Fusion of FGFR1, FGFR2, or FGFR3 (FUZE)

https://clinicaltrials.gov/ct2/show/NCT03834220?term=fuze&draw=2&rank=1